U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H16N6S
Molecular Weight 252.3407
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CIMETIDINE

SMILES

Cc1c(CSCCNC(=NC)NC#N)[nH]cn1

InChI

InChIKey=AQIXAKUUQRKLND-UHFFFAOYSA-N
InChI=1S/C10H16N6S/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14)

HIDE SMILES / InChI
Molecular Formula C10H16N6S
Molecular Weight 252.3407
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/cdi/cimetidine.html

Cimetidine is a histamine H2-receptor antagonist. It reduces basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin. It is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Cimetidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Cimetidine include an increase in gastric bacterial flora such as nitrate-reducing organisms. Cimetidine binds to an H2-receptor located on the basolateral membrane of the gastric parietal cell, blocking histamine effects. This competitive inhibition results in reduced gastric acid secretion and a reduction in gastric volume and acidity.

CNS Activity

CNS Penetrant
1174
Curator's Comment:: Enhanced cimetidine penetration of the blood brain barrier has been demonstrated in patients with liver disease.

Originator

Approval Year

1977
29
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
1131
 70.0 nM [Ki]
Inhibitor
3315
 1.2 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
4033
TAGAMET

Approved Use

Treating and preventing ulcers of the stomach and small intestine, and treating gastroesophageal reflux disease (GERD). It may be used for treating esophagitis (inflammation of the esophagus) caused by acid reflux and certain conditions that cause increased acid secretion (eg, Zollinger-Ellison syndrome).

Launch Date

8.0343361E11
Primary
Approved
4033
TAGAMET

Approved Use

Treating and preventing ulcers of the stomach and small intestine, and treating gastroesophageal reflux disease (GERD). It may be used for treating esophagitis (inflammation of the esophagus) caused by acid reflux and certain conditions that cause increased acid secretion (eg, Zollinger-Ellison syndrome).

Launch Date

8.0343361E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.056 μg/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/anda/98/75285_Cimetidine.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CIMETIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.22 μg × h/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/anda/98/75285_Cimetidine.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CIMETIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.4 h
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/anda/98/75285_Cimetidine.pdf
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CIMETIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
unhealthy, 50 years (range: 22-85 years)
n = 17
Health Status: unhealthy
Age Group: 50 years (range: 22-85 years)
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
Other AEs: Headache, Abdominal pain...
Other AEs:
Headache (2 patients)
Abdominal pain (2 patients)
Nausea (2 patients)
Anorexia (2 patients)
Vomiting (2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
20 g single, oral
Overdose
Dose: 20 g
Route: oral
Route: single
Dose: 20 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/92705
unhealthy, adult
n = 3
Health Status: unhealthy
Age Group: adult
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/92705
Sources:
https://pubmed.ncbi.nlm.nih.gov/92705
3 g 4 times / day multiple, oral
Overdose
Dose: 3 g, 4 times / day
Route: oral
Route: multiple
Dose: 3 g, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/74598
unhealthy, adult
n = 1
Health Status: unhealthy
Condition: duodenal ulcer
Age Group: adult
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/74598
Sources:
https://pubmed.ncbi.nlm.nih.gov/74598
300 mg 4 times / day multiple, respiratory
Recommended
Dose: 300 mg, 4 times / day
Route: respiratory
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aa4ee5b-b5be-4a98-5b8c-6f75e2b59e51
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aa4ee5b-b5be-4a98-5b8c-6f75e2b59e51
Sources:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aa4ee5b-b5be-4a98-5b8c-6f75e2b59e51
AEs

AEs

AESignificanceDosePopulation
Abdominal pain 2 patients
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
unhealthy, 50 years (range: 22-85 years)
n = 17
Health Status: unhealthy
Age Group: 50 years (range: 22-85 years)
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
Anorexia 2 patients
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
unhealthy, 50 years (range: 22-85 years)
n = 17
Health Status: unhealthy
Age Group: 50 years (range: 22-85 years)
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
Headache 2 patients
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
unhealthy, 50 years (range: 22-85 years)
n = 17
Health Status: unhealthy
Age Group: 50 years (range: 22-85 years)
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
Nausea 2 patients
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
unhealthy, 50 years (range: 22-85 years)
n = 17
Health Status: unhealthy
Age Group: 50 years (range: 22-85 years)
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
Vomiting 2 patients
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
unhealthy, 50 years (range: 22-85 years)
n = 17
Health Status: unhealthy
Age Group: 50 years (range: 22-85 years)
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/3520794
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
825
inhibitor
894
inhibitor
775

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
725

CYP3A4/5
122

CYP2C19
700

MATE1
143

OCT2
297

OAT3
290

MATE2
126

OCT1
254
OAT3
140

MATE1
64

MATE2
46
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
OCT2
298
 yes [IC50 110 uM]
OCT1
266
 yes [IC50 149 uM]
CYP1A2
805
 yes [IC50 200 uM]
CYP2D6
908
 yes [IC50 210 uM]
CYP3A4/5
142
 yes [IC50 480 uM]
yes (co-administration study)
Comment: Coadministration with midazolam: [AUC(0-12)] and AUC(0-∞) values for midazolam were 507.0 ± 265.1 (40%) and 786.1 ± 365.2 (50%) nmol/mL · h, respectively;
Page: 4.0
OAT3
291
 yes [IC50 79 uM]
CYP2C9
851
 yes [Inhibition 10 uM]
CYP2C19
738
 yes [Ki 157.8 uM]
MATE2
126
 yes [Ki 2.1 uM]
MATE1
145
 yes [Ki 3.8 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
MATE1
64
 yes
MATE2
46
 yes
OAT3
140
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
796
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:3699
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3699
ChemicalBook
CB31086794
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB31086794
ChemicalBook
CB4229414
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4229414
MolPort
MolPort-001-838-193
https://www.molport.com/shop/molecule-link/MolPort-001-838-193
MolPort
MolPort-003-895-998
https://www.molport.com/shop/molecule-link/MolPort-003-895-998
MolPort
MolPort-016-638-396
https://www.molport.com/shop/molecule-link/MolPort-016-638-396
MolPort
MolPort-020-313-426
https://www.molport.com/shop/molecule-link/MolPort-020-313-426
MolPort
MolPort-042-675-761
https://www.molport.com/shop/molecule-link/MolPort-042-675-761
Selleck Chemicals
Cimetidine(Tagamet)
http://www.selleckchem.com/products/Cimetidine(Tagamet).html
ZINC
ZINC000018115268
http://zinc15.docking.org/substances/ZINC000018115268
eMolecules
1107425
https://www.emolecules.com/cgi-bin/more?vid=1107425
eMolecules
19230646
https://www.emolecules.com/cgi-bin/more?vid=19230646
eMolecules
26714830
https://www.emolecules.com/cgi-bin/more?vid=26714830
eMolecules
6208997
https://www.emolecules.com/cgi-bin/more?vid=6208997
eMolecules
901649
https://www.emolecules.com/cgi-bin/more?vid=901649
PubMed

PubMed

TitleDatePubMed
Hemodynamic effects of H2-receptor antagonists.
1990 Nov
Effects of antihistaminics on locomotor activity in mice. Comparison with opiate and amphetamine-induced hyperactivity.
1991
Decreased histamine H1 receptors in the frontal cortex of brains from patients with chronic schizophrenia.
1991 Aug 15
Cimetidine inhibits catechol estrogen metabolism in women.
1991 Feb
[Cimetidine hepatitis].
1992 Dec 15
Cimetidine-dobutamine interaction?
1992 Nov
Polyuria and weight-loss associated with cimetidine.
1992 Sep
Activity of cathepsin B, D and L in rat cerebrum after cimetidine and famotidine administration.
2003
Radioprotective properties of histamine H2 receptor antagonists: present and future prospects.
2003 Jun
Bioequivalence and other unresolved issues in generic drug substitution.
2003 Nov
[Roles of histamine receptors in pain perception: a study using receptors gene knockout mice].
2003 Nov
Regulation of cytokine production in carcinoembryonic antigen stimulated Kupffer cells by beta-2 adrenergic receptors: implications for hepatic metastasis.
2004 Jun 25
Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3.
2004 May
Relative contribution of OAT and OCT transporters to organic electrolyte transport in rabbit proximal tubule.
2004 Nov
Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A).
2004 Oct 25
Carrier-mediated uptake of H2-receptor antagonists by the rat choroid plexus: involvement of rat organic anion transporter 3.
2004 Sep
Comparison of information on the pharmacokinetic interactions of Ca antagonists in the package inserts from three countries (Japan, USA and UK).
2005 Aug
Cimetidine-induced tubulointerstitial nephritis with both MPO-ANCA and PR3-ANCA.
2005 Dec
Metabolism of territrem B and C in liver microsomes from 14-wk-old Wistar rats is catalyzed by cytochrome P-450 3A.
2005 Feb 27
Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine.
2005 Jan
Comparative study of the speed of acid-suppressing effects of oral administration of cimetidine and famotidine.
2005 Jul
Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver.
2005 May
Enhanced antinociception by intracerebroventricularly administered orexin A in histamine H1 or H2 receptor gene knockout mice.
2005 Nov
Alteration of intracellular histamine H2 receptor cycling precedes antagonist-induced upregulation.
2005 Nov
A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters.
2005 Oct
Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
2006
Effect of endogenous histamine in the ventral hippocampus on fear memory deficits induced by scopolamine as evaluated by step-through avoidance response in rats.
2006 Apr 15
Cimetidine induces interleukin-18 production through H2-agonist activity in monocytes.
2006 Aug
In vitro availability of metformin in presence of h(2) receptor antagonists.
2006 Jan
Putting theory into practice: James Black, receptor theory and the development of the beta-blockers at ICI, 1958-1978.
2006 Jan
Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists.
2006 Mar
Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H+ antiporter in the kidney.
2006 Nov
Effects of histamine 2 receptor antagonists on endothelial-neutrophil adhesion and surface expression of endothelial adhesion molecules induced by high glucose levels.
2007 Jan-Feb
Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters.
2007 Jul 15
Cimetidine induces apoptosis of human salivary gland tumor cells.
2007 Mar
Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells.
2009 Apr
Androgen action via testicular peritubular myoid cells is essential for male fertility.
2009 Dec
Visions of drug discovery. Cimetidine (Tagamet).
2009 Feb
Ocular surface tumors.
2009 Jan
Gastroprotective activity of alkaloid extract and 2-phenylquinoline obtained from the bark of Galipea longiflora Krause (Rutaceae).
2009 Jul 15
Ligand diversity of human and chimpanzee CYP3A4: activation of human CYP3A4 by lithocholic acid results from positive selection.
2009 Jun
Antiulcer and anticonvulsant activity of Croton zambesicus.
2009 Oct
Size-dependent effects of nanoparticles on the activity of cytochrome P450 isoenzymes.
2010 Feb 1
Contribution of mast cells to the oedema induced by Bothrops moojeni snake venom and a pharmacological assessment of the inflammatory mediators involved.
2010 Feb-Mar
Drug interaction and pharmacist.
2010 Jul
Two cases of h(2)-receptor antagonist hypersensitivity and cross-reactivity.
2011 Apr
Hepatoprotective, antinociceptive and antioxidant activities of cimetidine, ranitidine and famotidine as histamine H2 receptor antagonists.
2011 Feb
OCT1 Expression in adipocytes could contribute to increased metformin action in obese subjects.
2011 Jan
Gastroprotective mechanisms of Citrus lemon (Rutaceae) essential oil and its majority compounds limonene and β-pinene: involvement of heat-shock protein-70, vasoactive intestinal peptide, glutathione, sulfhydryl compounds, nitric oxide and prostaglandin E₂.
2011 Jan 15
Involvement of histaminergic receptor mechanisms in the stimulation of NT-3 synthesis in astrocytes.
2011 Jun
Patents

Patents

04093621
2
04140783
2
04255425
2
04267337
2
05075291
2
JP2003530301A
2
JP2007008845A
4
JP3292732B2
9
JP4732696B2
34
JPH01299274A
2
JPH0225468A
2
JPH0245416A
2
JPH0276859A
2
JPH08157354A
2
JPH08512055A
12
JPS56104868A
2
JPS57203071A
2
JPS58174370A
2
JPS58188860A
2
JPS5852213A
2
JPS63190872A
2
JPS63192757A
2

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Duodenal Ulcer Parenteral: 300 mg IV or IM every 6 to 8 hours. Alternatively, a continuous IV infusion may be administered at a rate of 37.5 to 50 mg/hour, or up to a maximum rate of 100 mg/hour (2.4 g/day). Oral: 800 mg to 1600 mg once a day at bedtime. Alternatively, dosage regimens of 300 mg four times per day, with meals and at bedtime, or 400 mg twice daily, in the morning and at bedtime, have shown to be effective.
Route of Administration: Other
In Vitro Use Guide
Cimetidine (10(-7)M) inhibited IL-10 production and restored IL-12 secretion in LPS-treated murine DCs.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:52:14 UTC 2021
Edited
by admin
on Fri Jun 25 20:52:14 UTC 2021
Record UNII
80061L1WGD
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CIMETIDINE
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
CIMETIDINE [MI]
Common Name English
2-CYANO-1-METHYL-3-(2-(((5-METHYLIMIDAZOL-4-YL)METHYL)THIO)ETHYL)-GUANIDINE
Systematic Name English
CIMETIDINE [JAN]
Common Name English
CIMETIDINE [USAN]
Common Name English
BRUMETIDINA
Brand Name English
CIMETIDINE [IARC]
Common Name English
TAGAMET
Brand Name English
CIMAL
Brand Name English
CIMETIDINE [MART.]
Common Name English
ACINIL
Brand Name English
STOMEDINE
Brand Name English
CIMETIDINE [WHO-DD]
Common Name English
DYSPAMET
Brand Name English
GASTROMET
Common Name English
CIMETIDINE [INN]
Common Name English
CIMETIDINUM [WHO-IP LATIN]
Common Name English
ULCEDIN
Brand Name English
ULCOMEDINA
Common Name English
CIMETIDINE [WHO-IP]
Common Name English
GUANIDINE, N''-CYANO-N-METHYL-N'-(2-(((5-METHYL-1H-IMIDAZOL-4-YL)METHYL)THIO)ETHYL)-
Systematic Name English
CIMETIDINE [HSDB]
Common Name English
SKF-92334
Code English
CIMETIDINE [USP-RS]
Common Name English
ULCIMET
Brand Name English
CIMETIDINE [USP MONOGRAPH]
Common Name English
ACILOC
Brand Name English
CIMETIDINE [VANDF]
Common Name English
CIMETIDINE [EP MONOGRAPH]
Common Name English
CIMETIDINE [ORANGE BOOK]
Common Name English
NSC-335308
Code English
Classification Tree Code System Code
NCI_THESAURUS C29702
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
WHO-VATC QA02BA01
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
NDF-RT N0000000151
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
WHO-VATC QA02BA51
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
LIVERTOX 209
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
WHO-ATC A02BA01
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
WHO-ATC A02BA51
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
NDF-RT N0000175784
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
Code System Code Type Description
INN
3765
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
PRIMARY
CAS
51481-61-9
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
PRIMARY
NCI_THESAURUS
C374
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
PRIMARY
MESH
D002927
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
PRIMARY
MERCK INDEX
M3552
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
PRIMARY Merck Index
EPA CompTox
51481-61-9
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
PRIMARY
EVMPD
SUB06279MIG
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
PRIMARY
WIKIPEDIA
CIMETIDINE
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
PRIMARY
LACTMED
Cimetidine
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
PRIMARY
RXCUI
2541
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
PRIMARY RxNorm
HSDB
3917
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
PRIMARY
ChEMBL
CHEMBL30
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
PRIMARY
FDA UNII
80061L1WGD
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
PRIMARY
IUPHAR
1231
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
PRIMARY
DRUG BANK
DB00501
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
CIMETIDINE
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
PRIMARY Description: A white to off-white powder; odourless or with a faint odour.Solubility: Sparingly soluble in water; very soluble in methanol R.Category: Antiulcer drug.Storage: Cimetidine should be kept in a well-closed container.
PUBCHEM
2756
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
PRIMARY
ECHA (EC/EINECS)
257-232-2
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
PRIMARY
USP_CATALOG
1134062
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
PRIMARY USP-RS
DRUG CENTRAL
645
Created by admin on Fri Jun 25 20:52:14 UTC 2021 , Edited by admin on Fri Jun 25 20:52:14 UTC 2021
PRIMARY
Related Record Type Details
OAT-3
TRANSPORTER -> INHIBITOR
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
OCT-1
TRANSPORTER -> SUBSTRATE
CYTOCHROME P450 1A2
METABOLIC ENZYME -> INHIBITOR
POTENT
OCT-3
TRANSPORTER -> SUBSTRATE
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
OAT-3
TRANSPORTER -> SUBSTRATE
CYTOCHROME P450 2D6
METABOLIC ENZYME -> INHIBITOR
POTENT
MATE-2
TRANSPORTER -> INHIBITOR
MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1
TRANSPORTER -> SUBSTRATE
Vmax
MATE-2
TRANSPORTER -> SUBSTRATE
Vmax
MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1
TRANSPORTER -> SUBSTRATE
Km
MATE-2
TRANSPORTER -> SUBSTRATE
Km
OCT-2
TRANSPORTER -> SUBSTRATE
MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1
TRANSPORTER -> INHIBITOR
OCT-1
TRANSPORTER -> INHIBITOR
OCT-2
TRANSPORTER -> INHIBITOR
HISTAMINE H2 RECEPTOR
TARGET -> INHIBITOR
Related Record Type Details
Structure of CIMETIDINE HYDROXYMETHYL
METABOLITE -> PARENT
Structure of CIMETIDINE SULFOXIDE
METABOLITE -> PARENT
MAJOR
URINE
Related Record Type Details
Structure of CIMETIDINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966